405 related articles for article (PubMed ID: 35976170)
1. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
2. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
3. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
Lopez AT; Geskin L
Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
Gault A; Anderson AE; Plummer R; Stewart C; Pratt AG; Rajan N
Br J Dermatol; 2021 Aug; 185(2):263-271. PubMed ID: 33393076
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
6. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
[TBL] [Abstract][Full Text] [Related]
7. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM
Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP
J Immunother Cancer; 2017 Dec; 5(1):102. PubMed ID: 29254506
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
Sadik CD; Langan EA; Gutzmer R; Fleischer MI; Loquai C; Reinhardt L; Meier F; Göppner D; Herbst RA; Zillikens D; Terheyden P
Front Immunol; 2020; 11():588582. PubMed ID: 33708189
[TBL] [Abstract][Full Text] [Related]
9. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
10. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.
L'Orphelin JM; Cassecuel J; Kandolf L; Harwood CA; Tookey P; Junejo MH; Hogan S; Lebbé C; Appalla Z; Kränke TM; Pellacani G; Cerasuolo D; Dujovic B; Del Marmol V; Forschner A; Garbe C; Bataille V; Ressler JM; Sollena P; Dompmartin A; Peris K; Dreno B;
J Eur Acad Dermatol Venereol; 2023 Apr; ():. PubMed ID: 37042810
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
13. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
Tsiogka A; Bauer JW; Patsatsi A
Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
[TBL] [Abstract][Full Text] [Related]
14. Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
Olsson Ladjevardi C; Koliadi A; Rydén V; Inan El-Naggar A; Digkas E; Valachis A; Ullenhag GJ
Cancer Med; 2023 Jun; 12(12):13217-13224. PubMed ID: 37132258
[TBL] [Abstract][Full Text] [Related]
15. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
[TBL] [Abstract][Full Text] [Related]
17. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
[TBL] [Abstract][Full Text] [Related]
18. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
